Expanded access, sometimes called compassionate use, refers to the use of an investigational new drug outside of a clinical trial for patients with serious or life-threatening conditions who have exhausted their treatment options and are not eligible for, or able to participate in, a clinical trial.
Reveal Pharmaceuticals is committed to advancing new contrast agents for patients requiring medical imaging (e.g. MRI) to detect and visualize lesions in the central nervous system (CNS) and body.
We are working to bring our new manganese-based MRI contrast agent to patients as quickly and safely as possible through our clinical development program.
Because we are actively in clinical studies of our lead candidate, RVP-001, we are not currently providing access outside of clinical trials. At this time, we believe participation in a clinical trial is the optimal way to access these investigational agents to enable thorough evaluation and support regulatory approvals.
This policy is subject to change and may be revised by Reveal at any time.
Reveal is transforming medical insight, improving human health, and positively impacting the environment. Over 40M contrast-enhanced magnetic resonance imaging (MRI) scans are performed each year.
Current MRI contrast agents all cause accumulation of the heavy metal gadolinium in the brain and body of every patient, and drive rising levels of gadolinium in earth's surface waters.
Reveal’s patented contrast agents use manganese, which is essential for life. Reveal’s clinical stage product RVP-001 aims to directly replace current MRI contrast agents, benefiting patients and the planet.